To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have leiomyosarcoma of the uterus that has returned or continues to grow despite at least one but no more than two prior regimens of chemotherapy.
- At least 3 weeks must have passed since completion of prior therapy (1 week since hormonal therapy) and entry into the study.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. David Hyman at 646-888-4544.